Leishmania major-specific, CD4+, major histocompatibility complex class II-restricted T cells derived in vitro from lymphoid tissues of naive mice by unknown
Leishmaa/a major-specific,  CD4 +, Major 
Histocompatibility  Complex Class H-restricted T  Cells 
Derived In Vitro from Lymphoid Tissues of 
Naive Mice 
By Anuraj H. Shankar and Richard G. Titus 
From the Department of Tropical Public Health, Harvard School of Public Health, Boston, 
Massachusetts 02115 
Summary 
Several studies indicate that the outcome of experimental murine cutaneous leishmaniasis caused 
by Leishmania major (Lm) is determined by immunological events occurring shortly after infection. 
These events lead to outgrowth of either protective CD4 + T cells in the C57BL/6 mouse, which 
cures, or exacerbative cells in the BALB/c mouse, which succumbs to disease. Potential factors 
influencing the outgrowth of protective or exacerbative T cells include antigen-presenting cells 
(APC), cytokines, and parasite antigens. An in vitro system, in which one could precisely control 
the factors shaping early events in the T  cell response to Lm, would be very useful. To this 
end, we have examined the in vitro response of naive lymphocytes to Lm promastigotes. The 
data presented here show that Lm-specific CD4 + T cell receptor c~//~  + T cells can be generated 
in vitro from spleen and lymph node cell populations of naive mice. Furthermore, they can be 
obtained from the CD44 l~  (unprimed) population of T  lymphocytes, indicating that in vitro 
priming occurs. The ability to generate these T cells is dependent on the presence of live parasites 
and is not due to a parasite-derived nonspecific T  cell mitogen. Restimulation,  as assayed by 
proliferation, requires APC bearing syngeneic I-A. Optimal restimulation of the in vitro derived 
T ceils is achieved only when live promastigntes are used. The T cells do not proliferate in response 
to a frozen-and-thawed lysate of promastigotes, yet they exhibit mild reactivity to lysates prepared 
from heat-shocked promastigotes. Furthermore, they do not recognize two predominant antigens 
on the promastigote surface,  lipophosphoglycan and gp63.  T  cells derived in vitro with Lm 
show crossreactivity with live L.  donovani, less crossreactivity with live L.  mexicana, and no 
crossreactivity with live Badllus-Calmette-Guerin or live Brugia malayi microfilariae.  Finally, these 
early T  cells,  whether derived from healing C57BL/6  or nonhealing BALB/c mice, produce 
interleukin 2 (IL-2),  IL-4,  and interferon % 
I 
n experimental murine cutaneous leishmaniasis caused by 
Leishmania  major (Lm), t  it  is  well  known  that  some 
strains of mice overcome the infection whereas others suc- 
cumb to disease (1). Both cure and noncure responses are medi- 
ated  by  parasite-specific  CD4 +  T  cells  that  can  protect 
against or exacerbate leishmaniasis (2, 3). There are several 
ways mice can be immunologically manipulated so as to change 
the course of disease.  Noncuring BALB/c mice can be in- 
duced to control Lm infection after infusion of mAbs to IL-4 
(4), IL-2 (5), or CD4 (6). In addition, treatment with anti-/~ 
1 Abbreviations used in this paper: HSAg, heat-shock antigen; hsp,  heat- 
shock protein; Lra, Leishmania major; LNC,  lymph node cells;  LPG, 
lipophosphoglycan; NMS, normal mouse serum;  PIV, primary in vitro; 
SC, spleen cells. 
serum (7),  sublethal irradiation  (8),  administration of cy- 
closporin A (9), or induction of partial tolerance to Lm Ags 
(10) results in control of the infection. Conversely, mouse 
strains that normally cure are unable to resolve infection after 
infusion of mAb to IFN-3' (11) or anti-# treatment (12). Of 
particular interest to the present work is the observation that 
treatments with mAb to IL-4, IFN-3', and CD4, as well as 
irradiation and administration of cyclosporin A, must be given 
during the early phase of infection to be effective (4,  6,  8, 
9, 11). Similarly, treatment with anti-# affects primarily the 
early phase of infection since/~-suppressed mice exhibit normal 
disease profiles after adoptive transfer of T cells from infected 
untreated animals (12). These observations suggest that im- 
munological events occurring during the initial encounter 
between Lm and host immune system determine the subse- 
quent outcome of infection. 
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in vitro model system that mimics the in vivo response would 
be very useful.  Such a  system would allow precise control 
over conditions, i.e., Ag, cytokines, and APC, that may lead 
to outgrowth  of protective or exacerbative T  cells. 
To this end we have developed a procedure whereby Lm- 
specific T  cells can be generated in vitro from naive mice. 
We have shown that these T  cells generated by primary in 
vitro stimulation  (PIV T  cells) are analogous  to those iso- 
lated from mice after infection in that they are CD4 + TCR 
o~//5 +, have strong Lm-spedfic responses, are I-A restricted, 
and  produce IL-2,  IL-4,  and  IFN-% 
Materials and Methods 
Animals.  All mice were purchased as specific pathogen-free 
animals  and were used as young adults.  BALB/c mice were ob- 
tained  from  Taconic  Farms  (Germantown,  NY).  C57BL/6, 
C57BL/10, B10.BK/SgSn, B10.AQK, B10.A(SR)/SgSn, DBA/2, 
SWR/J, CBA/J, and CBA/CaH-T6J mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). BALB.B and B10.D2/nSn 
mice were from Harlan Olac Ltd. (Oxon, UK). 
Parasites, Antigens, Antibodies, and Cell Lines.  Lm was a clone 
of LV39 and was maintained as previously described (13). L. donovani 
(Sudan strain;  World Health Organization) and L. mexicana ama- 
zonensis (a clone of PH8[WR563] [14]) were maintained as for Lm. 
In all cases promastigotes from stationary phase cultures were used 
(15). Live Mycobacteriura boris BCG Montreal (lot 1012) was ob- 
tained from the Trudean Institute (Saranac Lake, NY). Brugia malayi 
microfilariae were isolated  from the peritoneal cavity of infected 
gerbils  as described (16) and were cultured for 10 d  at 37~  in 
DMEM supplemented with 10% FCS, penicillin,  streptomycin, 
and glutamine. Live microfilariae were used and were separated from 
nonviable parasites by their ability to emerge after embedding in 
0.5%  low-melt agarose  prepared in culture medium. 
Lm antigen (LmAg) was prepared by rapid freezing and thawing 
as described (6). Lm heat-shock Ag (HSAg) was prepared by cul- 
turing parasites for 24 h at 34~  followed by freezing and thawing. 
Lm metacyclic lipophosphoglycan (LPG) was kindly provided by 
D. Sacks (National Institutes of Health, Bethesda, MD) and recom- 
binant Lm gp63 was the gift ofR. McMaster (University of British 
Columbia, Vancouver,  Canada). 
The mAbs used in this study are listed in Table 1 and were used 
as cell culture supernatants unless  otherwise indicated. 
The OVA-specific  cell line was produced by immunizing BALB/c 
mice with OVA at the base of the tail as described (31). Briefly, 
7 d after immunization, draining lymph nodes were removed and 
cultured for 5 d with OVA.  Blast cells were isolated on discon- 
tinuous Percoll (Pharmacia,  Uppsala,  Sweden) density gradients 
and rested for 10 d. OVA-specific T cells were then isolated by pas- 
sage over a discontinuous Ficoll gradient as previously described (32). 
Priming of Lm-specific Cells In Vitra  Spleens from normal mice 
were aseptically removed and a single cell suspension was prepared. 
Cells were washed and resuspended at 5  x  10  + cell/ml in culture 
medium consisting of DMEM (13) supplemented with 5  x  10 -s 
M 2-ME and 0.5% normal mouse serum (NMS). Stationary phase 
Lm promastigotes were then added at 5  x  10S/ml. LmAg was 
used  at  a  final  concentration of 5  x  106 Lm  equivalents/ml. 
1 ml/well was then plated into 24-well culture plates (Costar, Cam- 
bridge, MA). After 3-7 d of incubation, blast cells were isolated 
on Percoll gradients. Lymph node cells (LNC) were prepared from 
popliteal, para-aortic, and inguinal lymph nodes and were processed 
as described for spleen cells (SC). 
Priming of Thy-l.2+CD44  ~  cells was accomplished as follows. 
Thy-l.2 + cells from naive BALB/c spleens were prepared using a 
cocktail of mAbs to B cell surface antigens (RA3-3A1, Jlld) and 
class II (MK-D6) followed by lysis with Low Tox Rabbit comple- 
ment (Accurate Chem, & Sci. Corp., Westbury, NY) and removal 
of dead cells by passage over Ficoll. The remaining cells were ;>95% 
Thy-l.2 + as assayed by flow cytometry. Cells  were then stained 
with anti-CD44 mAb, 1M7.8.1, and secondary antibody, PE-labeled 
goat anti-rat IgG preabsorbed with mouse Ig (Southern Biotech- 
nology Associates,  Inc., Birmingham,  AL).  CD44  l~  cells were 
isolated on an Epics cell sorter (Coulter Electronics Inc., Hialeah, 
FL) by selecting the lower 50% of the CD44  t~  population. These 
cells were combined with T cell-depleted splenocytes, <2% Thy- 
1.24, prepared by complement-mediated lysis using a mAb cock- 
tail of NEI-001, GK1.5, and H35-17.5. The relative proportions 
of these two populations in the combined mixture was such that 
the original T cell/non-T cell ratio was preserved: in this case, 2:3. 
Cells  were then cultured with Lra as described. 
An additional round of restimulation of PlV T cells was achieved 
by replating 5  x  10  s purified 7-d blasts,  5  x  106 irradiated (900 
red, +~  source)  syngeneic SC, and 5  x  10  s Lm/ml in 24-well 
culture plates. 5 d later, cells were harvested by passage over Ficoll. 
Flow Cytometry.  PIV T cells were incubated with hybridoma 
culture supematants  of the primary mAb supplemented with 0.02% 
azide and 1% NMS. Incubation with the appropriate secondary 
antibody, FITC-labeled goat anti-rat IgG preabsorbed with mouse 
Ig (Tago, Inc., Palo Alto, CA) or FITC-labeled goat anti-hamster 
IgG preabsorbed with rat and mouse IgG (Caltag Labs., San Fran- 
cisco, CA), was performed in culture medium supplemented with 
5% FCS and 0.02% azide. Cells were then fixed in PBS with 3.0% 
paraformaldehyde. Analysis was performed on either an Ortho 50-H 
or FACScan  |  (Becton Dickinson & Co., Mountain View, CA) flow 
cytometer. 
Antigen Specificity and Cytoleine Production of  PIV T Cells.  Before 
restimulation,  7-d  PIV  T  cells  were  rested  (5  x  10S/ml)  in 
DMEM supplemented with 0.5% NMS for 3--4 d. This allowed 
PIV T  cells to become quiescent, thereby reducing background 
levels in proliferation assays. After rest, dead cells were removed 
by passage over Ficoll.  Triplicate  wells were prepared on 96-well 
microtiter plates (Costar) with 10  + irradiated  (1,500 rad) syngeneic 
SC and 5  x  104 PIV T  cell blasts  in 100 #1 of culture medium 
with 0.5%  NMS and appropriate Ag. All species of Leishmania 
were added at 10S/well; LmAg and HSAg were added to a final 
concentration of 106 Lm equivalents/ml. Lm recombinant gp63 
was used at 13 gg/ml and Lm LPG at 25 gg/ml. Bacillus-Calmette- 
Guerin  (BCG)  was  used  at  2  x  10  s  live  BCG/well  and  live 
/~ ma/ay/microfilariae at 100 organisms/well.  Proliferation was mea- 
sured by addition of 1 #Ci [3H]thymidine/well 48 h after plating, 
which was determined to be optimal. Cultures were harvested 24 h 
later,  and  degree  of proliferation was  assessed by  scintillation 
counting. Identical conditions were used for restimulating OVA- 
specific cells, with OVA used at  100 gg/ml. 
To generate cytokines, 7-d PIV T cells (106/ml) were restimu- 
lated in 24-well plates with 5  x  10  + irradiated  (900 rad) syngeneic 
SC and 106 Lm/ml.  Supernatants were harvested 24 h later. 
Cytokine Analysis.  IL-2  and Ib4 were measured in supernatants 
by bioassays that used indicator cells whose proliferation is affected 
by the presence of a particular cytokine: Ib2 was detected using 
CTLb2 (33; CTLL was maintained in recombinant human [rh]IL-2; 
Cetus Corp., Emeryville, CA); IL-4 was detected using 11.6 (34; 
11.6  was  maintained  in  recombinant  murine  [rm]IL-4;  A. 
102  Leishmania  major-spedfic CD4 + T Cells Derived In Vitro from Naive Mice Glasebrook, Eli Lilly, Indianapolis, IN). The effect of a sample su- 
pernatant on the proliferation of CTLL or 11.6 was assessed by 
[3H]thymidine incorporation, and units per milliliter of a partic- 
ular cytokine in the test supernatant were calculated from a stan- 
dard curve obtained with either rmlL-2 or rmlL-4 (Genzyme, Cam- 
bridge, MA). Specificity was assessed using blocking anti-Ib2 mAb 
$4B6 or anti-Ib4 mAb 11Bll. 
IFN-qr activity was detected by capture ELISA performed on 
96-well Falcon  |  3912 Micro Test IIF  M plates (Becton Dickinson 
Labware, Oxnard,  CA) using the rat anti-IFN-3, mAb XMG1.2 
as the primary antibody and hamster anti-IFN-'y mAb 5.102.12 
as the secondary antibody. XMG1.2 and 5.102.12  were prepared 
by ammonium sulfate precipitation from cell culture supernatant 
and ascites,  respectively.  Binding of the secondary mAb was de- 
tected using horseradish peroxidase-conjugated goat anti-hamster 
Ig preabsorbed to rat Ig (Caltag Labs.), and the ELISA was devel- 
oped with 3,3',5,5'-tetramethylbenzidine (TMB) peroxidase sub- 
strate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). 
Units per milliliter were calculated from a standard curve obtained 
with rmlFN-3, (a gift of Genentech, South San Francisco,  CA). 
Results 
Naive SC Undergo T Cell Blastogenesis in the Presence of  Live 
Lra Promastigotes.  SC from naive BALB/c mice were coin- 
cubated with live Lm promastigotes. The kinetics of the en- 
suing blastogenic response are shown in Fig.  1. As early as 
day 3, a blastogenic response could be observed; small numbers 
of blast calls,  0.3-1.0%  of initial  splenocytes plated,  could 
be isolated and restimulated to proliferate in the presence of 
Lm and fresh irradiated  syngeneic SC as APC.  By day 7,  a 
potent blastogenic response was clearly discernable. Analysis 
Table  1.  mAbs to Murine Antigens  Used in  This Study 
Antibody  Specificity  Reference 
AF6-120.1.2  I-A  bk"  17 
GK1.5  CD4  18 
H35-17.2  CD8  19 
H57-597  TCRc~fl  20 
J11d  Heat-stable antigen  21 
M1/70  Mac-1  22 
M5/114  I-AbaI-E  dk  23 
M5/49.4  Thy-1  23 
MK-D6  bA  d  24 
NEI-001  Thy-l.2  New England  Nuclear 
(Boston,  MA) 
RA3-3A1  B220  25 
$4B6  IL-2  26 
XMG  1.2  IFN-3'  27 
1M7.8.1  CD44  28 
5.102.12  IFN-3'  29 
11Bll  IL-4  30 
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Figure  1.  Kinetics of the PIV response to BALB/c mice. The develop- 
ment of PIV T cells from BALB/c SC was monitored by harvesting cul- 
tures at the indicated time points and isolating blast cells over Percoll gra- 
dients as detailed in Materials and Methods. The number of blast cells 
was determined by counting in a hemacytometer. Calculations were based 
on the assumption that spleen cell populations are composed of 40% 
T cells. Therefore, the percent yield =  100x [blasts/(SC plated)(0.4)]. 
by flow  cytometry showed  that  these  7-d blast  cells  were 
60-75% Thy-l.2 + CD4 +. This generally represented a yield 
of 2-7% of the cells present in the initial culture, or ~5-17% 
of T cells initially present. After an additional 5 d of stimula- 
tion  using  fresh syngeneic irradiated  SC  as APC  and Lm, 
the blast cells were >95%  Thy-I.2+CD4 + and >95% TCR 
cr/fl §  This potent  blastogenic  response was not  observed 
if naive splenocytes were cocultured  in  the  absence of any 
exogenous  Ag  or in  the  presence of 100  #g/ml  OVA. 
It was possible that the PIV response to Lm was a charac- 
teristic of only certain inbred mouse strains.  To test this we 
examined several strains of mice (Table 2) differing in genetic 
Table  2.  Mouse  Strains from which PIV T  Cells Could 
Be Obtained 
Response* 
Strain  to Lm  H-25  I-E~  Mls types 
BALB/c  S  d  +  b 
BALB.B  S  b  -  b 
SWR/J  S  q  +  b 
DBA/2  S/R  d  +  a 
C57BL/6  R  b  -  b 
B10.A(5R)/SgSn  R  b  +  b 
B10.D2/nSn  R  d  +  b 
CBA/CaH-T6J  R  k  +  b 
CBA/J  R  k  +  a 
* Compiled from references I and 35; S, susceptible (noncuring); R, resis- 
tant (curing). 
* H-2 haplotype as indicated in reference 36. 
5 Conventional Mls type as compiled in reference 37. 
103  Shankar  and Titus background, resistance or susceptibility to Lm, H-2 haplo- 
type, expression of I-E, and Mls type. As indicated, all mouse 
strains were capable of generating a potent T cell blastogenic 
response. 
Most experiments were carried out with SC since they were 
easily obtained in large numbers. However, it was conceiv- 
able that the observed  effect was unique to the spleen and 
not obtainable with LNC. Since LNC and not the spleen 
would be the site of initial exposure to Lm during natural 
infection, this was an important consideration. Therefore, 
we cultured naive LNC from C57BL/6 and BALB/c mice 
with live Lm. A similar blastogenic response was obtained, 
confirming that this effect was not unique to SC. 
We next wanted to ascertain if the responding cells were 
indeed naive lymphocytes that were primed in vitro or memory 
cells responding to a crossreactive antigen present in Lm. This 
was determined by incubating purified CD44 l~  unprimed 
(38) T  cells, prepared from spleen,  with Thy-l.2-depleted 
splenocytes and live Lm. Lm-specific T cell blasts were again 
obtained, confirming that T cell priming was taking place. 
Finally, we wanted to determine if the PIV response  re- 
quired the presence  of live Lm  or if certain Lm  Ag drove 
this response. We, therefore, incubated naive SC with freeze- 
thawed Lm promastigote Ag. No blastogenic response was 
observed even when the amount of  LmAg added was 10 times 
that present when live parasites  were used. 
Since it is normally difficult to obtain Ag-specific primary 
T  cell  responses  in vitro,  we wanted to determine if the 
CD4 § PIV T  cells were conventional T  cells with respect 
to  their  MHC  restriction,  Ag  specificity,  and  cytokine 
production. 
Conditions Required for Restimulation of PIV T Cells.  7-d 
PIV T  cells were restimulated under various conditions to 
assess their proliferative  requirements. As shown in Fig. 2 
A, PIV T cells did not proliferate constitutively, nor did they 
respond to either Lm or syngeneic SC alone. Only when both 
APC  and Lm  were present did the cells proliferate.  This 
was also observed  for PIV T  cells derived from LNC and 
CD44  l~  T  cells (data not shown). 
The data presented above did not eliminate the possibility 
that PIV T cells were being stimulated by a T cell mitogen 
produced by living parasites in conjunction with SC. To test 
this, we incubated an OVA-specific CD4 + T  cell line with 
live Lm and irradiated SC. As can be seen in Fig. 2 B, OVA- 
specific cells did not proliferate in response to Lm yet responded 
strongly to OVA. This indicates that the PIV response is not 
driven by a nonspecific  mitogen. 
Analysis of  PIV T Cell MHC Restriction.  We then deter- 
mined if the MHC restriction pattern of PIV T  cells was 
identical to that observed with conventional CD4 + T cells, 
i.e., (a) inhibition of proliferation by anti-MHC class II mAb; 
(b) inhibition by anti-CD4 mAb; and (c) H-2-restricted rec- 
ognition of Ag. Results shown in Fig. 3 indicate that prolifer- 
ation of PIV T cells was inhibited by anti-I-A/I-E and anti- 
CD4 antibodies. In addition, proliferation was unaffected  by 
controls consisting of either an isotype-matched antibody, 
anti-CD8, or another antibody that binds to the cell surface 
of macrophages, anti-Mac-1. 
Results concerning the MHC restriction of PIV T  cells 
are presented in Table 3. In experiment 1, PIV T cells were 
obtained using naive spleens from B10.BR mice. These cells 
were restimulated with Lm and APC consisting of irradiated 
SC from various H-2 congenic mice of the B10 series. APC 
from B10.AQR mice supported proliferation of B10.BR PIV 
T cells, indicating that class I loci K and D were not involved 
in Ag recognition. This would be anticipated given that PIV 
T cells are CD4 +  8-, although class I-restricted CD4 + cells 
have been observed  (39).  Furthermore, APC from B10.D2 
mice did not effectively present Ag to B10.BR PIV T cells, 
suggesting that class II is involved, as would be expected from 
Fig. 3. Finally, APC from CBA/CaH-T6J mice did support 
proliferation, confirming that these PIV T cells were MHC 
restricted and were not being stimulated by genes  outside 
the MHC region. This requirement for H-2-compatible APC 
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Figure  2.  Restimulation  of PlV 
T cells requires APC and Lra and 
is not the result of a nonspecific 
mitogen. (.4) 7-d PIV T cells from 
BALB/c mice were obtained and 
rested as described  in Materials  and 
Methods. The cells were restimu- 
lated as indicated: SC, 106 irradi- 
ated (1,500 tad) BALB/c  SC; TC, 
5 x  104 PIV T cells; Lm, 10  s live 
stationary  phase Lm promastigotes. 
(B) OVA-specific  T ceUs were  gener- 
ated from  BALB/c  mice  as described 
in Materials  and Methods.  The cells 
were restimulated  using  conditions 
given for A: TC, 5  x  104 OVA- 
specific T cells; OVA, 100/~g/ml 
OVA. Proliferation  was assessed  as 
described  in Materials  and Methods. 
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Figure 3.  Restimulation  of PIV T cells is inhibited by anti-CD4 and 
anti-I-A/l-E antibodies. 7-d PIV T cell blasts from BALB/c mice were 
obtained, rested, and restimulated  as described  in Materials and Methods. 
All antibodies  were  added as 1:10  dilutions  of  hybridoma  culture  superna- 
rant. Anti-I-A/I-E, M5/114; anti-CD4, GK1.5; anti-CD8, H35-17.2; anti- 
Mac-l, M1/70. 
was a characteristic of PIV T  cells derived from all mouse 
strains tested. 
Experiment 2 (Table 3) determined if PIV T  cells were 
I-A or I-E restricted. PIV T cells from B10.A(5R) mice were 
restimulated with syngeneic APC and Lra in the presence 
or absence of anti-I-A  b mAb. The proliferative response in 
the presence of anti-I-A  b was only 10% of the control. In 
addition, B10.A(5R) PIV T cells were restimulated using APC 
from C57BL/10 (I-AbI-E nun) mice, and the proliferative re- 
sponse was virtually identical to that observed with syngeneic 
APC. The role of I-A was also observed with B10.D2 (I-A  a) 
and BALB/c (I-A  d) mice in that anti-I-A  d antibody inhibited 
restimulation  when  syngeneic APC  were used  (data  not 
shown).  Last,  PIV  T  cells  were  readily  obtained  from 
C57BL/10 and BALB.B mice, both of which do not express 
I-E. Taken together, these results indicate that PIV T  cells 
are I-A restricted, as are CD4 + Lm-specific T  cells isolated 
from infected mice (40). 
Antigenic Specificity of PIV T  Cells,  We next examined 
the antigenic specificity of PIV T  cells  (Fig.  4). Although 
PIV T cells did proliferate vigorously upon restimulation with 
live Lm, they did not proliferate to a preparation of total Lm 
promastigote Ag (LmAg). No significant responses were ob- 
tained to either the major surface glycoprotein ofLm (gp63) 
or to the major surface glycoconjugate ofLm (LPG), although 
both  of these  Ag  preparations  strongly  stimulated  LNC 
isolated  from  infected mice  (data  not  shown).  Since Lm 
promastigotes undergo heat shock in the PIV system, we also 
examined the response of PIV T  cells to Ag prepared from 
heat-shocked promastigotes. Interestingly, a response to this 
preparation was observed. Finally, PIV T  cells elicited with 
Lm were found to proliferate to live L. donovani and to a lesser 
extent to live L.  m. amazonensis.  No proliferation was ob- 
tained with either an unrelated intracellular organism, live 
BCG,  or  with  an  unrelated  extracellular  organism,  live 
JR  malayi  microfilariae. 
Cytokine Production by PIV  T  Cells.  For these studies, 
cytokine-containing cell culture supernatants were generated 
by restimulating 7-d PIV T calls with live Lm and low dose-- 
irradiated (900 rad) SC as APC. Low dose irradiation was 
used so that the radiosensitive APC functions of  B cells would 
Table 3.  PIV T  Cells Exhibit I-A-restn'cted Antigen Recognition 
H-2 region  Proliferation 
Exp.  PIV T cell  APC  K  A  E  D  mAb  response 
%  +_  SEM 
1  B10.BR/SgSn  B10.BR/SgSn  k  k  k  k  -  100  _+  2 
B10.AQR  q  k  k  d  -  115  _+  3 
B10.D2/nSn  d  d  d  d  -  1 _+  3 
CBA/CaH-T6J  k  k  k  k  -  99  +  3 
2  B10.A(5R)/SgSn  B10.A(5R)/SgSn  b  b  b  d  -  100  _+  3 
B10.A(SR)/SgSn  b  b  b  d  Anti-I-A b  10  _+  3 
C57BL/10  b  b  -  b  -  92  _+  3 
7-d PIV T cells from the indicated mouse strains were derived  and restimulated with Lm promastigotes  as detailed in Materials and Methods. Anti-I-A  s 
antibody AF6-120.1.2 was added at a 1:10 dilution of hybridoma culture supernatant. Proliferation  was assessed as described  in Materials and Methods. 
Data from two independent experiments have been normalized for comparison. Proliferative  values ranged from 5  x  104 to 10  s cpm. 
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Figure 4.  Antigenic specificity 
ofPIV T ceils. 7-d PlV T cells from 
BALB/c  mice  were  restimulated 
with the indicated antigens: L raaj, 
L  don, L  raex, 105 live stationary 
phase  promastigotes/well;  L  raaj 
LmAg, 105 Lm eqnivalents/weil of 
freeze-thawed promastigotes; L maj 
HSAg,  105 Lm equivalents/well of 
freeze-thawed heat-shocked promas- 
tigotes; L  maj gp63, recombinant 
Lra gp63 at 13 #g/ml; L majLPC, 
purified  Lra metacyclic  promastigote 
LPG at 25/~g/ml; BCG, 2  x  105 
live Bacilhs-Calmette-Guerin/wdl; 
B ma/ay/, 100 live R  ma/a~ micro- 
falaria/weil. Results are a composite 
of three independent ~periments 
that have been normalized for com- 
parison. Proliferative values ranged 
from 5  x  104 to 105 cpm. 
remain intact (41), thereby mimicking as much as possible 
the in vivo environment. Representative results are shown 
in Fig. 5.7-d PIV T cell blasts from both nonhealing BALB/c 
and healing C57BL/6 mice produced IL-2, IL-4, and IFN-% 
Interestingly, when high dose (1,500 rad)-irradiated SC were 
used as APC, no IL-4 could be detected in culture superna- 
tants,  although IL-2 and IFN-3' were still  produced. 
I  []  C57BL/6 
IL-2  []  BALB/c 
IL-4 
IFN .~~ 
- 
.......  t  .......  i 
10  100  1000 
U  / ml _+ SEM 
Figure 5.  Cytokine production of PIV T ceils. 7-d PIV T ceil blasts 
from C57BL/6 and BALB/c mice were isolated and restimulated with fresh 
syngeneic irradiated  (900 rad) spleen cells and live Lra as described in 
Materials and Methods. Supematants were collected 24 h after restimula- 
tion and examined for cytokine activity by bioassay or ELISA as outlined 
in Materials and Methods. 
Discussion 
This report demonstrates that Lm-specific T  cells can be 
generated in vitro from lymphoid tissues  of normal mice. 
Importantly, we have further shown that the T cells gener- 
ated in the PIV system arise from the naive CD44  l~  T cell 
population, indicating that genuine priming occurs. Further- 
more, PIV T cells resemble conventional Lm-specific T cells 
in that they: (a) are CD4 + TCK o~lfl+;  (b) are restricted 
to the I-A determinant of MHC class II; and (c) produce IL-2, 
IL-4,  and IFN-% 
The in vitro priming phenomenon described here does not 
appear to be unique to Lm, as we have also observed in vitro 
blastogenic responses to L.  m. amazonesis, L.  tt  brasiliensis, 
and L. donovani using culture conditions identical to those 
described here for Lm. Live L. donovani amastigotes can also 
induce the proliferation of parasite-specific  T  ceils if coin- 
cubated with naive murine SC (Paul Kaye, personal commu- 
nication).  Interestingly, in vitro stimulation of naive lym- 
phocytes is not restricted to either T cells or to routine systems. 
For example, polyclonal B cell activation using normal mu- 
rine splenocytes and Lra promastigote lysates has been ob- 
served (42). In addition, cells from nonexposed human beings 
have  been reported to  respond in vitro  to L.  amazonesis, 
L. donovani, or Lm (43, 44), to Plasmodiura fakiparura  (45), 
and to Trypanosoma cruzi (46).  Thus, it is possible  that the 
ability to generate primary T and B cell blastogenic responses 
in vitro from naive hosts is not only a capability of Le/sh- 
mania but may well be a common property of protozoan para- 
sites. This could account for the potent immunogenic response 
to many of these infections. For example, in mice it has been 
observed that as early as 3 d after infection with Lm, parasite- 
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LNC (47). 
The facility with which Lm-specific T cell blasts can be 
obtained by primary in vitro immunization is remarkable. 
The blastogenic response to live parasites can occur even in 
the absence of specialized  conditions such as oxygenated media, 
rocking of cultures, daily addition of nutrients (48), or even 
2-ME, an important supplement for other in vitro priming 
systems  (49).  Therefore, it would be useful to know how 
such  a  response is  generated and which factors,  such  as 
cytokines, accessory  cells, or antigens, may be involved. Second, 
the in vivo effects of those factors governing the PIV response 
should be examined. 
Initially, we speculated that the Lm-specific T cells gener- 
ated in the PIV system were responding to a parasite super- 
antigen. Superantigens are highly immunogenic  proteins pro- 
duced by  some  pathogenic bacteria,  and  are  capable  of 
stimulating naive T cells in vitro by activating cells bearing 
certain Va regions regardless of the antigenic specificity of 
the TCR itself (50).  However, several observations argue 
against a leishmanial superantigen being responsible for the 
PIV response.  First, PIV T cells exhibit clear I-A-restricted 
recognition of antigen (Table 3). Although superantigens may 
prefer certain I-A types more than others, strict syngeneic 
requirements are not observed (51, 52). Second, whereas the 
PIV T cells generated here are exclusively CD4 +, foreign su- 
perantigens generally stimulate both CD8 + and CD4 + T 
cells (52). In addition, if a superantigen were responsible for 
the PIV response,  one would expect to see a change in the 
proportional representation of predominant V~ regions in 
stimulated T cell populations as compared with naive ones. 
In the naive BALB/c mouse, •25%  of splenic T  cells ex- 
press Vt~8.1, 8.2, or 8.3, and 10% express V/36, accounting 
for '~35% of all splenic T cells. Therefore, by examining the 
percentage of cells bearing Va8 or V~6 and the change in 
the V~8/V~6 ratio,  most superantigen effects can be de- 
tected. For example, when BALB/c splenocytes are exposed 
in vitro to the superantigen staphylococcal  enterotoxin B, 
which binds V~3, 7, 8.1, 8.2, 8.3, and 11 (53), the V~8/V~6 
ratio of 4-d T cell blasts increased sevenfold (53). Similarly, 
when Y. enterocolitica superantigen containing lysates are used, 
which bind V~3, 7, 8.1, 9, and 11 (54),  the Va8/V~6 ratio 
decreased 40%  (54).  In our PIV system, however, we find 
that V~ usage of 7-d PIV T cells is 25% Va8.1, 8.2, or 8.3, 
and 10% V~6, giving a V~8/V~6 ratio of 2.5:1, identical to 
that of naive BALB/c splenic T cells. Collectively,  these data 
do not formally rule out a role for a superantigen-like mole- 
cule in our system but they do suggest that if a superantigen 
is acting, a novel mechanism is involved. 
Given that a superantigen activity is unlikely, the mecha- 
nism(s) underlying the PIV phenomenon and the parasite 
antigen(s) that the PIV T cells recognize remain unknown. 
It has been shown, however, that in vitro infection of macro- 
phages from both curing and noncuring mouse strains results 
in production of large amounts of IL-1 (55; H. R. Chak- 
kalath and R. G. Titus, unpublished data), which could facili- 
tate T  cell priming. With regard to antigens, it has been 
demonstrated that live Lm can act as an adjuvant when coin- 
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jected with peptides (56).  This effect can be mimicked by 
substituting for live organisms the 70-kD  heat-shock pro- 
tein (hsp) of M.  bovis, M. tuberculosis, or the GroEL hsp of 
Escherichia coli (56). Since the 70-kD hsp's are among the most 
conserved proteins throughout evolution (57) and are potent 
antigens of many pathogens, including Lm (58, 59), it is pos- 
sible that hsp's are partially responsible  for stimulating the 
PIV response. The recognition of heat-shocked promastigote 
antigen by PIV T cells (Fig. 4) is consistent with this idea. 
Along with hsp's other proteins may be expressed during trans- 
formation from promastigote to amastigote. Given these con- 
siderations, we are currently examining the roles of IL-1, hsp, 
and amastigote antigens in the PIV system. 
The data presented here show that both curing and non- 
curing mouse strains produce PIV T cell blasts (Table 2), which 
secrete IL-2, IL-4, and IFN-y (Fig. 5), upon exposure to Lm 
in vitro. Several studies indicate that IL-2 (60, 61), IL-4 (62), 
and other cytokines (63-65) can promote Leishmania survival 
both in vitro and in vivo. It is, therefore,  conceivable that 
the early immune response to Leishmania  could directly pro- 
mote parasite survival. If an initial parasite-specific immune 
response benefits the parasite, inhibition of this early response 
might benefit the host. It is noteworthy that all treatments 
that enable noncuring BALB/c mice to control a primary in- 
fection (4-10) would inhibit T cell priming and expansion. 
Likewise, partial tolerance to Lm antigens in curing mouse 
strains C3H/HeN and (B6  x  B10.D2)F1 also results in less 
severe disease (A. Shankar, unpublished data). Moreover, both 
irradiated  and  CD4 §  T  cell-depleted mice harbor  fewer 
parasites  than untreated controls during the early phase of 
infection (66, 67). Hence, attenuating the initial immune re- 
sponse to Lm does appear to facilitate cure. As mentioned, 
the early response should, therefore, be exacerbative. In fact, 
we have adoptively transferred  7-d PIV T  cell blasts  from 
both  BALB/c  and  C57BL/6  mice  into  naive  syngeneic 
recipients and observed that lesion development was poten- 
tiated (data not shown). Thus, Lm can foster development 
of exacerbative cells shortly after infection such that its sur- 
vival and replication is facilitated. This early response, though 
beneficial for the parasite in all mouse strains, may differen- 
tially influence the subsequent cure or noncure response ob- 
served in mice of different genotypes. Therefore, a better un- 
derstanding of factors governing the PIV response and its 
potential effects in vivo may have implications for beneficial 
immunomodulation of leishmaniasis. 
As mentioned, 7-d PIV T cell populations from both resis- 
tant and susceptible  mice produced IL-2,  IL-4,  and IFN-3, 
(Fig. 5). Hence, early in a PIV response, the responding cells 
are either Th0 cells or some mixture of Thl and Th2. This 
is consistent with recent data examining the early response 
to Lm in which both curing and noncuring mouse strains 
produced IL-4 and IFN-'), (47, 68). These studies were per- 
formed with lymph node cells taken shortly after infection 
and stimulated in vitro. Since varying potentials for cytokine 
production can exist between peripheral lymph nodes and 
SC (69, 70), we are currently examining LNC-derived PIV 
T cells for the cytokine these cells produce and the effect the 
cells have on infection with Lm in vivo. In addition, cytokine secretion patterns in long-term cultures of PIV T  cells are 
being monitored to detect differentiation into Thl or Th2 
phenotypes. 
In experimental murine cutaneous leishmaniasis caused by 
Lm, a correlation exists between Thl parasite-specific T cell 
responses and disease resolution, and Th2 responses and dis- 
ease progression (reviewed in reference 5). However, experi- 
ments involving T cell clones and lines from several different 
strains of mice indicate that a Thl or Th2 phenotype is not 
an indicator of protective or exacerbative function (13,  31, 
71-73).  Attempts  to  more precisely identify Thl  or Th2 
cytokines  regulating  disease  outcome  have  also  yielded 
conflicting results.  Infusing mAb to IFN-3r is detrimental 
while mAbs to IL-4 or IL-2 can be protective (4, 5, 11, 74). 
However, injection of either IFN-3' or IL-4 has little effect 
on disease (4, 47, 74, 75) unless coadministered with adju- 
vant, in which case both are protective (47, 76). Thus, a com- 
ple~ picture is emerging with respect to cytokines and preferen- 
tial outgrowth of protective or exacerbative T cells after Lm 
infection of mice. 
Clearly, the ability to precisely manipulate in vitro the con- 
ditions under which Lm-specific T  cells first encounter an- 
tigen would facilitate the study of the complex interactions 
leading to outgrowth of protective or exacerbative T  cells. 
The in vitro system involving Lm that  has been developed 
and analyzed in this study shares many characteristics with 
the natural  in vivo response to Lm during  the early phase 
of infection. Therefore, this system may offer a tool to inves- 
tigate factors responsible for development of various Th call 
subsets and protective or exacerbative T  cells.  For example, 
since  cytokines  have been  shown  to  affect  outgrowth  of 
Th cell subsets (77-81), exogenously added cytokines, both 
alone and in combination, can be included at the inception 
of a PIV response to determine whether this alters the nature 
of the responding Lm-specific T  cell.  In this respect,  it  is 
intriguing that the PIV T cells produce appreciable amounts 
of IL-4 since recent antigen-specific in vitro priming studies 
indicate that  IL-4 is produced only when it is also present 
during priming  (82), suggesting that Lm may induce IL-4 
production by some novel mechanism.  Last,  APC function 
can be examined. A role for B cells in the PlV system is dearly 
suggested by the fact that  IL-4 was not produced by PIV 
T  cells  restimulated  with  1,500-tad irradiated  SC that  are 
deficient in B cell antigen  presentation,  but was produced 
when 900-tad irradiated SC were used in which B cell pre- 
sentation does occur. Several laboratories have, in fact, demon- 
strated effects of APC type on cytokine production by T cells 
(83-85). We can, therefore, test various APC such as Lange- 
rhans cells, monocytes, or B cells in the PIV system to deter- 
mine whether certain APC selectively activate protective or 
exacerbative Lm-specific T  cells. 
The advantage of the PIV approach is that control can be 
maintained  over early events that  shape the Lm-specific T 
cell response, i.e., T cell priming and outgrowth. The influence 
of factors such as cytokines, APC, and parasite antigens can, 
therefore, be precisely determined. Such an experimental ap- 
proach may help unravel the mechanisms determining  sus- 
ceptibility and resistance in cutaneous leishmaniasis. 
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